Scopus
YÖKSİS DOI Eşleşti
SJR Q4
Development of a Robust, Rapid and Reliable Tandem Mass Spectrometry Method for the Measurement of Sildenafil, Bosentan and their Major Metabolites
Indian Journal of Clinical Biochemistry · Şubat 2026
YÖKSİS Kayıtları
Development of a Robust, Rapid and Reliable Tandem Mass Spectrometry Method for the Measurement of Sildenafil, Bosentan and their Major Metabolites
Indian Journal of Clinical Biochemistry · 2024 ESCI
Prof. Dr. ABDULLAH SİVRİKAYA →
Development of a Robust, Rapid and Reliable Tandem Mass Spectrometry Method for the Measurement of Sildenafil, Bosentan and their Major Metabolites
Indian Journal of Clinical Biochemistry · 2024 ESCI
Prof. Dr. ALİ ÜNLÜ →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
2022 ISSN: 0970-1915 EBSCO, İndex Copernicus
Prof. Dr. ALİ ÜNLÜ →
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
2022 ISSN: 0970-1915 ESCI
Prof. Dr. ALİ ÜNLÜ →
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
2024 ISSN: 0970-1915 ESCI Q4
Prof. Dr. ALİ ÜNLÜ →
Development of a Robust, Rapid and Reliable Tandem Mass Spectrometry Method for the Measurement of Sildenafil, Bosentan and their Major Metabolites
2024 ISSN: 0970-1915 ESCI
Prof. Dr. ABDULLAH SİVRİKAYA →
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
2024 ISSN: 0970-1915 EMBASE
Prof. Dr. ALİ ÜNLÜ →
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
2024 ISSN: 0970-1915 ESCI
Prof. Dr. SEDAT ABUŞOĞLU →
The Role of L-Arginine Metabolism and Endogenous Dimethylarginine in Chronic Venous Insufficiency
2025 ISSN: 0970-1915 ESCI
Prof. Dr. SEDAT ABUŞOĞLU →
Makale Bilgileri
ISSN09701915
Yayın TarihiŞubat 2026
Cilt / Sayfa41 · 113-119
Scopus ID2-s2.0-85190382395
Özet
Pulmonary arterial hypertension (PAH) is a lethal, progressive disease with a complex pathogenesis. Bosentan, a dual endothelin receptor antagonist, and sildenafil, a phosphodiesterase type 5 inhibitor, are used to treat PAH. In this study, we aimed to develop a liquid chromatography-tandem mass spectrometry method (LC–MS/MS) to measure the levels of bosentan, sildenafil, and their active metabolites in patients with PAH. We have developed an LC–MS/MS measurement procedure using a liquid–liquid extraction to measure serum drug concentrations and validated the procedure according to Clinical and Laboratory Standards Institute (CLSI) protocols. Finally, the validated method was used to measure the levels of sildenafil, bosentan, and their metabolite in pediatric PAH patients. The method was linear in the range of 0.975–1000 ng/ml and 0.76–3125 ng/ml for sildenafil and bosentan, respectively. LOQ values of sildenafil and bosentan were determined as 1.95 and 1.50 ng/ml, respectively. A method for measuring the levels of sildenafil and bosentan was developed that is rapid, robust, inexpensive, and requires a small serum volume. In addition, the validated method measured these drugs’ levels and metabolites in pediatric patients with PAH. The results show that the established method can routinely monitor drug levels.
Yazarlar (7)
1
Mohammad Ahmad Bik
ORCID: 0000-0003-1577-6525
2
Duygu Eryavuz Onmaz
ORCID: 0000-0001-8564-1824
3
Karam Mazin Kamil Gharab
4
Fadime Karaman
ORCID: 0000-0002-4728-6355
5
Sedat Abusoglu
ORCID: 0000-0002-2984-0527
6
Abdullah Sivrikaya
7
Ali Ünlü
ORCID: 0000-0002-9991-3939
Anahtar Kelimeler
Bosentan, PAH, Sildenafil
Tandem mass spectrometry
Validation
Kurumlar
Mustansiriyah University
Baghdad Iraq
Selçuk Tip Fakültesi
Konya Turkey
Scimago Dergi (ISSN Eşleşmesi)
Indian Journal of Clinical Biochemistry
Q4
SJR Skoru0,265
H-Index61
YayıncıSpringer
ÜlkeIndia
Clinical Biochemistry (Q4)